<?xml version="1.0" encoding="utf-8"?>
<export-example>
  <doc>
    <id>530</id>
    <completedYear>2016</completedYear>
    <publishedYear>2016</publishedYear>
    <thesisYearAccepted/>
    <language>deu</language>
    <pageFirst>23</pageFirst>
    <pageLast>29</pageLast>
    <pageNumber/>
    <edition/>
    <issue/>
    <volume>20</volume>
    <type>articlewildau</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>1</belongsToBibliography>
    <completedDate>2016-03-21</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="deu">ECS-Komplex – ein neuer Biomarker bei Wachstumshormonstörungen?</title>
    <abstract language="deu">Störungen im Metabolismus des Wachstumshormons können sich als Wachstumshormonmangel oder -überschuss (Akromegalie) äußern. In beiden Fällen handelt es sich um seltene Krankheiten, die aufwendig behandelt werden müssen, da jeder Patient anders auf seine jeweilige Medikation anspricht. Zur Bestimmung des individuellen Ansprechverhaltens auf die medikamentöse Behandlung wird Insulin-like Growth Factor 1 verwendet, das jedoch als unzuverlässig für die Therapiekontrolle gilt. Um die Diagnostik und Therapie von Wachstumshormonstörungen zu verbessern, wurde in dieser Pilotstudie der Nutzen des neuen potenziellen Biomarkers Elongin B/C-Cullin5-Socs-box Komplex (ECS-Komplex) überprüft. Die fünf Proteine des Komplexes üben zusammen einen negativen Feedback-Mechanismus auf den Wachstumshormonrezeptor aus und regulieren ihn in Abhängigkeit vom Wachstumshormonspiegel im Blut. Für diese Pilotstudie wurden vier Patienten mit Wachstumshormondefizienz und 15 Patienten mit Akromegalie rekrutiert. Die Messung von Unterschieden in der Expression der Gene auf RNA-Ebene in Blutproben der Patienten erlaubt erste Aussagen über deren Eignung als therapeutische Marker für diese Krankheiten.</abstract>
    <abstract language="eng">Growth hormone (GH) dysfunctions can occur as a GH-deficiency (GHD) or an overproduction of GH, leading to acromegaly. Both are rare diseases, which have to be treated for many years before the correct individual dosage is found and a mitigation of symptoms can be achieved. Current medical therapy is determined by the levels of the insulin-like growth factor-1, which is considered to be an unreliable theranostic tool. In order to improve the diagnosis and therapy of patients with GH-dysfunctions, we investigated the benefits of the novel potential biomarker Elongin B/C-Cullin5-Socs-box complex (ECS-complex). Together, these proteins regulate the growth hormone receptor levels according to the blood GH concentration through a negative feedback loop. For this study, we were able to recruit four patients with a GHD and 15 patients&#13;
with acromegaly.&#13;
&#13;
The detected differential expression of the ECS-complex in patients with growth hormone dysfunctions allows for first conclusions about the potential of those proteins as predictive biomarker molecules for individualized therapies.</abstract>
    <parentTitle language="deu">Wissenschaftliche Beiträge 2016</parentTitle>
    <identifier type="issn">0949-8214</identifier>
    <identifier type="doi">10.15771/0949-8214_2016_1_3</identifier>
    <identifier type="urn">urn:nbn:de:kobv:526-opus4-5308</identifier>
    <enrichment key="ZSTiteliD">16238</enrichment>
    <enrichment key="DataCiteUrl">https://commons.datacite.org/doi.org/10.15771/0949-8214_2016_1_3</enrichment>
    <licence>Creative Commons - CC BY-NC-ND 3.0 DE - Namensnennung - Nicht-kommerziell - Keine Bearbeitung 3.0 Deutschland</licence>
    <author>Wilhelm Gossing</author>
    <author>Lars Radke</author>
    <author>Marcus Frohme</author>
    <author>Henrik Biering</author>
    <collection role="ddc" number="612">Humanphysiologie</collection>
    <collection role="ddc" number="616">Krankheiten</collection>
    <collection role="Publikationen_der_TH_Wildau" number="">Wissenschaftliche Beiträge</collection>
    <collection role="institutes" number="">Fachbereich Ingenieur- und Naturwissenschaften</collection>
    <collection role="open_access" number="">open_access</collection>
    <collection role="green_open_access" number="3">Diamond Open Access</collection>
    <thesisPublisher>Technische Hochschule Wildau</thesisPublisher>
    <file>https://opus4.kobv.de/opus4-th-wildau/files/530/ECS-Komplex.pdf</file>
  </doc>
  <doc>
    <id>1380</id>
    <completedYear>2021</completedYear>
    <publishedYear/>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst/>
    <pageLast/>
    <pageNumber/>
    <edition/>
    <issue>2</issue>
    <volume>9</volume>
    <type>article</type>
    <publisherName>MDPI</publisherName>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>1</belongsToBibliography>
    <completedDate>--</completedDate>
    <publishedDate>2021-02-17</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">The ElonginB/C-Cullin5-SOCS-Box-Complex Is a Potential Biomarker for Growth Hormone Disorders</title>
    <abstract language="eng">Insulin-like growth factor 1 (IGF-1) is the standard biochemical marker for the diagnosis and treatment control of acromegaly and growth hormone deficiency (GHD). However, its limitations necessitate the screening for new specific and sensitive biomarkers. The elonginB/C-cullin5-SOCS-box-complex (ECS-complex) (an intracellular five-protein complex) is stimulated by circulating growth hormone (GH) and regulates GH receptor levels through a negative feedback loop. It mediates the cells’ sensitivity for GH and therefore, represents a potent new biomarker for those diseases. In this study, individual ECS-complex proteins were measured in whole blood samples of patients with acromegaly (n = 32) or GHD (n = 12) via ELISA and compared to controls. Hierarchical clustering of the results revealed that by combining the three ECS-complex proteins suppressor of cytokine signaling 2 (SOCS2), cullin-5 and ring-box protein 2 (Rbx-2), 93% of patient samples could be separated from controls, despite many patients having a normal IGF-1 or not receiving medical treatment. SOCS2 showed the best individual diagnostic performance with an overall accuracy of 0.93, while the combination of the three proteins correctly identified all patients and controls. This resulted in perfect sensitivity and specificity for all patient groups, which demonstrates potential benefits of the ECS-complex proteins as clinical biomarkers for the diagnostics of GH-related diseases and substantiates their important role in GH metabolism.</abstract>
    <parentTitle language="eng">Biomedicines</parentTitle>
    <identifier type="issn">2227-9059</identifier>
    <identifier type="urn">urn:nbn:de:kobv:526-opus4-13802</identifier>
    <enrichment key="opus.import.date">2021-03-03T00:39:07+00:00</enrichment>
    <enrichment key="opus.source">sword</enrichment>
    <enrichment key="opus.import.user">sword</enrichment>
    <enrichment key="opus.import.file">attachment; filename=deposit.zip</enrichment>
    <enrichment key="opus.import.checksum">5f9612610681c311e8884bade974ab20</enrichment>
    <enrichment key="SourceTitle">Gossing, W.; Radke, L.; Biering, H.; Diederich, S.; Mai, K.; Frohme, M. The ElonginB/C-Cullin5-SOCS-Box-Complex Is a Potential Biomarker for Growth Hormone Disorders. Biomedicines 2021, 9, 201. https://doi.org/10.3390/biomedicines9020201</enrichment>
    <enrichment key="DOI_VoR">https://doi.org/10.3390/biomedicines9020201</enrichment>
    <licence>Creative Commons - CC BY - Namensnennung 4.0 International</licence>
    <author>Wilhelm Gossing</author>
    <author>Lars Radke</author>
    <author>Henrik Biering</author>
    <author>Sven Diederich</author>
    <author>Knut Mai</author>
    <author>Marcus Frohme</author>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>acromegaly</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>growth hormone deficiency</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>biomarker</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>SOCS2</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>liquid biopsy</value>
    </subject>
    <subject>
      <language>eng</language>
      <type>uncontrolled</type>
      <value>pituitary</value>
    </subject>
    <collection role="ddc" number="570">Biowissenschaften; Biologie</collection>
    <collection role="institutes" number="">Fachbereich Ingenieur- und Naturwissenschaften</collection>
    <collection role="open_access" number="">open_access</collection>
    <collection role="Import" number="import">Import</collection>
    <collection role="Funding" number="">Publikationsfonds der TH Wildau</collection>
    <collection role="green_open_access" number="1">Gold Open Access</collection>
    <thesisPublisher>Technische Hochschule Wildau</thesisPublisher>
    <file>https://opus4.kobv.de/opus4-th-wildau/files/1380/biomedicines-09-00201-v2.pdf</file>
  </doc>
</export-example>
